Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection
Authors
Keywords
-
Journal
MOLECULAR THERAPY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-10-22
DOI
10.1016/j.ymthe.2021.10.008
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice
- (2021) Juan García-Arriaza et al. JOURNAL OF VIROLOGY
- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutralizing aptamers block S/RBD‐ACE2 interactions and prevent host cell infection
- (2021) Xiaohui Liu et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs
- (2021) Nanda Kishore Routhu et al. IMMUNITY
- Characterization of Critical Determinants of ACE2–SARS CoV-2 RBD Interaction
- (2021) Emily E. F. Brown et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
- (2021) Denis Y Logunov et al. LANCET
- Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry
- (2021) Taha Azad et al. MOLECULAR THERAPY
- Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
- (2021) Dami A. Collier et al. NATURE
- Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins
- (2021) Kim M. Bouwman et al. PLoS Pathogens
- Localized and Systemic Immune Responses against SARS-CoV-2 Following Mucosal Immunization
- (2021) Shaswath S. Chandrasekar et al. Vaccines
- Cellular and Humoral Immune Responses in Mice Immunized with Vaccinia Virus Expressing the SARS-CoV-2 Spike Protein
- (2021) Jake C. Harbour et al. JOURNAL OF IMMUNOLOGY
- Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
- (2021) Sandile Cele et al. NATURE
- SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia
- (2021) Douglas B. Cines et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8+ T cell activation in COVID-19 patients
- (2021) Sunil Kumar Saini et al. Science Immunology
- Antibodies and Vaccines Target RBD of SARS-CoV-2
- (2021) Long Min et al. Frontiers in Molecular Biosciences
- SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19
- (2021) Lize M. Grobbelaar et al. BIOSCIENCE REPORTS
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- (2020) Peng Zhou et al. NATURE
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
- (2020) Daniel Wrapp et al. SCIENCE
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies
- (2020) Chunyan Yi et al. Cellular & Molecular Immunology
- Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial
- (2020) Till Koch et al. LANCET INFECTIOUS DISEASES
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
- (2020) Jun Lan et al. NATURE
- Site-specific glycan analysis of the SARS-CoV-2 spike
- (2020) Yasunori Watanabe et al. SCIENCE
- Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2
- (2020) James Brett Case et al. Cell Host & Microbe
- The Nucleocapsid Protein of SARS–CoV-2: a Target for Vaccine Development
- (2020) Noton K. Dutta et al. JOURNAL OF VIROLOGY
- SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
- (2020) Kizzmekia S. Corbett et al. NATURE
- ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
- (2020) Neeltje van Doremalen et al. NATURE
- Controlling the SARS-CoV-2 spike glycoprotein conformation
- (2020) Rory Henderson et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans
- (2020) Jose Mateus et al. SCIENCE
- Freeze-Drying Formulations Increased the Adenovirus and Poxvirus Vaccine Storage Times and Antigen Stabilities
- (2020) Ye Chen et al. VIROLOGICA SINICA
- The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients
- (2020) Lakshmanane Premkumar et al. Science Immunology
- Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
- (2020) Luca Piccoli et al. CELL
- SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
- (2020) Christopher O. Barnes et al. NATURE
- SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition
- (2020) Annika Nelde et al. NATURE IMMUNOLOGY
- The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform
- (2020) Ariane Volkmann et al. VACCINE
- Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor
- (2020) Jinsung Yang et al. Nature Communications
- IL-12 DNA Displays Efficient Adjuvant Effects Improving Immunogenicity of Ag85A in DNA Prime/MVA Boost Immunizations
- (2020) María Paula Morelli et al. Frontiers in Cellular and Infection Microbiology
- SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors
- (2020) Alina S. Shomuradova et al. IMMUNITY
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- (2020) Merryn Voysey et al. LANCET
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutralizing antibodies targeting SARS-CoV-2 spike protein
- (2020) Shi Xiaojie et al. Stem Cell Research
- Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform
- (2020) Flavia Chiuppesi et al. Nature Communications
- Structural and functional comparison of SARS-CoV-2-spike receptor binding domain produced in Pichia pastoris and mammalian cells
- (2020) Scientific Reports
- Deletion of Apoptosis Inhibitor F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer Therapy
- (2019) Adrian Pelin et al. Molecular Therapy-Oncolytics
- Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox
- (2019) Phillip R. Pittman et al. NEW ENGLAND JOURNAL OF MEDICINE
- ORF6 and ORF61 Expressing MVA Vaccines Impair Early but Not Late Latency in Murine Gammaherpesvirus MHV-68 Infection
- (2019) Baila Samreen et al. Frontiers in Immunology
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protective efficacy of monovalent and trivalent recombinant MVA-based vaccines against three encephalitic alphaviruses
- (2018) Wei-Gang Hu et al. VACCINE
- Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines
- (2018) Arwen F. Altenburg et al. Scientific Reports
- Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-Δ4 with a Set of Gene Deletions on Several Viral Pathways
- (2018) Ernesto Mejías-Pérez et al. Molecular Therapy-Oncolytics
- Humoral Immunity to Primary Smallpox Vaccination: Impact of Childhood versus Adult Immunization on Vaccinia Vector Vaccine Development in Military Populations
- (2017) Bonnie M. Slike et al. PLoS One
- Recombinant vaccinia vector-based vaccine (Tiantan) boosting a novel HBV subunit vaccine induced more robust and lasting immunity in rhesus macaques
- (2017) Yao Deng et al. VACCINE
- HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection
- (2015) Qiang Liu et al. AIDS
- Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector
- (2015) Guido Wollmann et al. VIROLOGY
- Genome Scale Patterns of Recombination between Coinfecting Vaccinia Viruses
- (2014) L. Qin et al. JOURNAL OF VIROLOGY
- Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
- (2013) C. J. Breitbach et al. CANCER RESEARCH
- Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies
- (2013) F. Song et al. JOURNAL OF VIROLOGY
- The vaccinia virus A56 protein: a multifunctional transmembrane glycoprotein that anchors two secreted viral proteins
- (2011) B. C. DeHaven et al. JOURNAL OF GENERAL VIROLOGY
- Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles
- (2011) Paul A. Goepfert et al. JOURNAL OF INFECTIOUS DISEASES
- Preexisting Vaccinia Virus Immunity Decreases SIV-Specific Cellular Immunity but Does Not Diminish Humoral Immunity and Efficacy of a DNA/MVA Vaccine
- (2010) S. Kannanganat et al. JOURNAL OF IMMUNOLOGY
- Altered CD8 + T Cell Immunodominance after Vaccinia Virus Infection and the Naive Repertoire in Inbred and F 1 Mice
- (2009) Inge E. A. Flesch et al. JOURNAL OF IMMUNOLOGY
- A Novel Replication-Competent Vaccinia Vector MVTT Is Superior to MVA for Inducing High Levels of Neutralizing Antibody via Mucosal Vaccination
- (2009) Xiaoxing Huang et al. PLoS One
- A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma
- (2008) Kristopher J. Kimball et al. GYNECOLOGIC ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started